Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five ...

Corcept Therapeutics (NasdaqCM:CORT) saw a remarkable 36% increase in its share price in the last quarter, driven by several key developments. The company's significant announcement on March 31, ...

Corcept Therapeutics Incorporated’s CORT share price has dipped by 7.02%, which has investors questioning if this is right ...

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...

Adding afuresertib to paclitaxel did not improve outcomes in patients with platinum-resistant ovarian cancer in a phase 2 trial.

Corcept Therapeutics Incorporated , a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by ...

Corcept Therapeutics (CORT) announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating ...

Mid-cap stocks surged in the past week, including CORT, COOP, and CRWV. GOOG may rent AI servers from CRWV. PRGS and LOAR ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...